Bóvüló lehetóségek és stratégiai megfontolások, újabb eljárások a felnóttkori akut myeloid leukaemia diagnosztikájában és kemoterápiájában.

Translated title of the contribution: Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia

Research output: Contribution to journalArticle

Abstract

The WHO classification of adultory acute myeloid leukemia puts the main emphasis on prognosis, based mainly upon cytogenetic findings and gene-expression profiles. The complex prognostic assessment provides a more solid basis for early therapeutic stratification. This review focuses mainly on medical therapy. Induction phase is quite uniform, it consists of antracyclin and cytosin arabinosid. High-dose cytosin arabinosid is the predominant tool of postinduction therapy, especially in the favorable cytogenetic pattern cases. All-trans retinoic acid resulted in extremely good results in the promyelocytic cases, and this therapy seems to be advantageous in respect of acute DIC, too. Arsenic trioxide could be the drug of choice in relapsed promyelocytic leukemia. Some new agents are promising in refractory or relapsed cases, i.e. antibodies (Mylotarg) or farnesyltransferase inhibitors. The near future may bring about new therapeutic approaches, involving immunotherapy (dendritic cell vaccines) or gene-therapy as well.

Original languageHungarian
Pages (from-to)1769-1777
Number of pages9
JournalOrvosi Hetilap
Volume144
Issue number36
Publication statusPublished - Sep 7 2003

Fingerprint

Acute Myeloid Leukemia
Drug Therapy
Cytogenetics
Farnesyltranstransferase
Therapeutics
Dacarbazine
Tretinoin
Transcriptome
Genetic Therapy
Immunotherapy
Dendritic Cells
Leukemia
Vaccines
Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{a6f7dc97a6074608a47d67a0e670d3c5,
title = "B{\'o}v{\"u}l{\'o} lehet{\'o}s{\'e}gek {\'e}s strat{\'e}giai megfontol{\'a}sok, {\'u}jabb elj{\'a}r{\'a}sok a feln{\'o}ttkori akut myeloid leukaemia diagnosztik{\'a}j{\'a}ban {\'e}s kemoter{\'a}pi{\'a}j{\'a}ban.",
abstract = "The WHO classification of adultory acute myeloid leukemia puts the main emphasis on prognosis, based mainly upon cytogenetic findings and gene-expression profiles. The complex prognostic assessment provides a more solid basis for early therapeutic stratification. This review focuses mainly on medical therapy. Induction phase is quite uniform, it consists of antracyclin and cytosin arabinosid. High-dose cytosin arabinosid is the predominant tool of postinduction therapy, especially in the favorable cytogenetic pattern cases. All-trans retinoic acid resulted in extremely good results in the promyelocytic cases, and this therapy seems to be advantageous in respect of acute DIC, too. Arsenic trioxide could be the drug of choice in relapsed promyelocytic leukemia. Some new agents are promising in refractory or relapsed cases, i.e. antibodies (Mylotarg) or farnesyltransferase inhibitors. The near future may bring about new therapeutic approaches, involving immunotherapy (dendritic cell vaccines) or gene-therapy as well.",
author = "M. Udvardy",
year = "2003",
month = "9",
day = "7",
language = "Hungarian",
volume = "144",
pages = "1769--1777",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Bóvüló lehetóségek és stratégiai megfontolások, újabb eljárások a felnóttkori akut myeloid leukaemia diagnosztikájában és kemoterápiájában.

AU - Udvardy, M.

PY - 2003/9/7

Y1 - 2003/9/7

N2 - The WHO classification of adultory acute myeloid leukemia puts the main emphasis on prognosis, based mainly upon cytogenetic findings and gene-expression profiles. The complex prognostic assessment provides a more solid basis for early therapeutic stratification. This review focuses mainly on medical therapy. Induction phase is quite uniform, it consists of antracyclin and cytosin arabinosid. High-dose cytosin arabinosid is the predominant tool of postinduction therapy, especially in the favorable cytogenetic pattern cases. All-trans retinoic acid resulted in extremely good results in the promyelocytic cases, and this therapy seems to be advantageous in respect of acute DIC, too. Arsenic trioxide could be the drug of choice in relapsed promyelocytic leukemia. Some new agents are promising in refractory or relapsed cases, i.e. antibodies (Mylotarg) or farnesyltransferase inhibitors. The near future may bring about new therapeutic approaches, involving immunotherapy (dendritic cell vaccines) or gene-therapy as well.

AB - The WHO classification of adultory acute myeloid leukemia puts the main emphasis on prognosis, based mainly upon cytogenetic findings and gene-expression profiles. The complex prognostic assessment provides a more solid basis for early therapeutic stratification. This review focuses mainly on medical therapy. Induction phase is quite uniform, it consists of antracyclin and cytosin arabinosid. High-dose cytosin arabinosid is the predominant tool of postinduction therapy, especially in the favorable cytogenetic pattern cases. All-trans retinoic acid resulted in extremely good results in the promyelocytic cases, and this therapy seems to be advantageous in respect of acute DIC, too. Arsenic trioxide could be the drug of choice in relapsed promyelocytic leukemia. Some new agents are promising in refractory or relapsed cases, i.e. antibodies (Mylotarg) or farnesyltransferase inhibitors. The near future may bring about new therapeutic approaches, involving immunotherapy (dendritic cell vaccines) or gene-therapy as well.

UR - http://www.scopus.com/inward/record.url?scp=0642304498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642304498&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 1769

EP - 1777

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -